{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:46:57Z","timestamp":1791082017823,"version":"4.1.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>The prolactin receptor (PRLR) is a member of the lactogen\/cytokine receptor family, which mediates multiple actions of prolactin (PRL). PRL is a major hormone in the proliferation\/differentiation of breast epithelium that is essential for lactation. It is also involved in breast cancer development, tumor growth and chemoresistance. Human PRLR expression is controlled at the transcriptional level by multiple promoters. Each promoter directs transcription\/expression of a specific non-coding exon 1, a common non-coding exon 2 and coding exons E3-11. The identification of exon 11 of PRLR led to finding of alternative spliced products and two novel short forms (SF) that can inhibit the long form (LF) of PRLR activity with relevance in physiological regulation and breast cancer. Homo and heterodimers of LF and SF are formed in the absence of PRL that acts as a conformational modifier. Heterodimerization of SF with LF is a major mechanism through which SF inhibits some signaling pathways originating at the LF. Biochemical\/molecular modeling approaches demonstrated that the human PRLR conformation stabilized by extracellular intramolecular S\u2212S bonds and several amino acids in the extracellular D1 domain of PRLR SF are required for its inhibitory actions on PRLR LF-mediated functions. Studies in breast cancer cells demonstrated that the transcription of PRLR was directed by the preferentially utilized PIII promoter, which lacks an estrogen responsive element. Complex formation of non-DNA bound ER\u03b1 dimer with Sp1 and C\/EBP\u03b2 dimers bound to their sites at the PRLR promoter is required for basal activity. Estradiol induces transcriptional activation\/expression of the PRLR gene, and subsequent studies revealed the essential role of autocrine PRL released by breast cancer cells and CDK7 in estradiol-induced PRLR promoter activation and upregulation. Other studies revealed stimulation of the PRLR promoter activity and PRLR LF protein by PRL in the absence of estrogen <jats:italic>via<\/jats:italic> the STAT5\/phospho-ER\u03b1 activation loop. Additionally, EGF\/ERBB1 can induce the transcription of PRLR independent of estrogen and prolactin. The various regulatory modalities contributing to the upregulation of PRLR provide options for the development of therapeutic approaches to mitigate its participation in breast cancer progression and resistance.<\/jats:p>","DOI":"10.3389\/fendo.2022.949396","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T07:13:01Z","timestamp":1663225981000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness"],"prefix":"10.3389","volume":"13","author":[{"given":"Raghuveer","family":"Kavarthapu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Dufau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/B978-1-4831-9827-9.50019-8","article-title":"The comparative endocrinology of prolactin","volume":"24","author":"Bern","year":"1968","journal-title":"Recent Prog Horm Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2000.80.4.1523","article-title":"Prolactin: Structure, function, and regulation of secretion","volume":"80","author":"Freeman","year":"2000","journal-title":"Physiol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-17-6-639","article-title":"Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects","volume":"17","author":"Ben-Jonathan","year":"1996","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.3.0334","article-title":"Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice","volume":"19","author":"Bole-Feysot","year":"1998","journal-title":"Endocr Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0092-8674(88)90488-6","article-title":"Cloning and expression of the rat prolactin receptor, a member of the growth hormone\/prolactin receptor gene family","volume":"53","author":"Boutin","year":"1988","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/mend-3-9-1455","article-title":"Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells","volume":"3","author":"Boutin","year":"1989","journal-title":"Mol Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(90)92337-Y","article-title":"Isolation and characterization of two novel rat ovarian lactogen receptor cDNA species","volume":"168","author":"Zhang","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11578","DOI":"10.1038\/ncomms11578","article-title":"A combined computational and structural model of the full-length human prolactin receptor","volume":"7","author":"Bugge","year":"2016","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.3.5659","article-title":"The human prolactin receptor gene structure and alternative promoter utilization: the generic promoter hPIII and a novel human promoter hP(N)","volume":"84","author":"Hu","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102109200","article-title":"Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11","volume":"276","author":"Hu","year":"2001","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/er.2011-1040","article-title":"Molecular mechanisms of prolactin and its receptor","volume":"33","author":"Brooks","year":"2012","journal-title":"Endocr Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2014.04.006","article-title":"Impact of subdomain D1 of the short form S1b of the human prolactin receptor on its inhibitory action on the function of the long form of the receptor induced by prolactin","volume":"1840","author":"Kang","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/er.2001-0036","article-title":"The role of prolactin in mammary carcinoma","volume":"24","author":"Clevenger","year":"2003","journal-title":"Endocr Rev"},{"key":"B14","article-title":"Prolactin and human tumorigenesis","volume":"22","author":"Fernandez","year":"2010","journal-title":"J Endocr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.747810","article-title":"The relevant participation of prolactin in the genesis and progression of gynecological cancers","volume":"12","author":"Ram\u00edrez-de-Arellano","year":"2021","journal-title":"Front Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0065-2571(88)90027-1","article-title":"Prolactin as a mammalian mitogen and tumor promoter","volume":"27","author":"Buckley","year":"1988","journal-title":"Adv Enzyme Regul"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10911-008-9063-y","article-title":"Prolactin and breast cancer etiology: An epidemiologic perspective","volume":"13","author":"Tworoger","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/JOE-10-0069","article-title":"New concepts in prolactin biology","volume":"206","author":"Bernichtein","year":"2010","journal-title":"J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.05.009","article-title":"Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge","volume":"179","author":"Goffin","year":"2017","journal-title":"Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0665","article-title":"A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development","volume":"73","author":"Tworoger","year":"2013","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0108","article-title":"Targeting prolactin receptor (PRLR) signaling in PRLR-positive breast and prostate cancer","author":"O'Sullivan","year":"2016","journal-title":"Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800685105","article-title":"Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors","volume":"105","author":"Bogorad","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/endo.133.1.8319561","article-title":"Visualization of gene expression of short and long forms of prolactin receptor in the rat","volume":"133","author":"Ouhtit","year":"1993","journal-title":"Endocrinology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/endo.136.9.7649097","article-title":"The prolactin receptor in the fetal rat: cellular localization of messenger ribonucleic acid, immunoreactive protein, and ligand-binding activity and induction of expression in late gestation","volume":"136","author":"Royster","year":"1995","journal-title":"Endocrinology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2011.12.010","article-title":"The WSXWS motif in cytokine receptors is a molecular switch involved in receptor activation: insight from structures of the prolactin receptor","volume":"20","author":"Dagil","year":"2012","journal-title":"Structure"},{"key":"B26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1042\/BJ20141243","article-title":"Intrinsically disordered cytoplasmic domains of two cytokine receptors mediate conserved interactions with membranes","volume":"468","author":"Haxholm","year":"2015","journal-title":"Biochem J"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.4267\/2042\/38132","article-title":"PRLR (prolactin receptor)","volume-title":"Atlas Genet cytogenet oncol haematol","author":"Tsai-Morris","year":"2011"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)54897-3","article-title":"A prolactin-dependent immune cell line (Nb2) expresses a mutant form of prolactin receptor","volume":"266","author":"Ali","year":"1991","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41523-021-00243-7","article-title":"The human intermediate prolactin receptor is a mammary proto-oncogene","volume":"7","author":"Grible","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0964","article-title":"Prolactin exerts a prosurvival effect on human spermatozoa via mechanisms that involve the stimulation of akt phosphorylation and suppression of caspase activation and capacitation","volume":"151","author":"Pujianto","year":"2010","journal-title":"Endocrinology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/me.2005-0291","article-title":"Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization","volume":"20","author":"Qazi","year":"2006","journal-title":"Mol Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1677\/JME-09-0101","article-title":"Short form 1b human prolactin receptor down-regulates expression of the long form","volume":"44","author":"Tan","year":"2010","journal-title":"J Mol Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1021\/bi7013882","article-title":"S2 deletion variants of human PRL receptors demonstrate that extracellular domain conformation can alter conformation of the intracellular signaling domain","volume":"47","author":"Tan","year":"2008","journal-title":"Biochemistry"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2010.01.008","article-title":"Impact of prolactin receptor isoforms on reproduction","volume":"21","author":"Binart","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1019","article-title":"Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma","volume":"64","author":"Meng","year":"2004","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01716-08","article-title":"Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor","volume":"29","author":"Xie","year":"2009","journal-title":"Mol Cell Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1477-7827-7-87","article-title":"Prolactin signaling through the short isoform of the mouse prolactin receptor regulates DNA binding of specific transcription factors, often with opposite effects in different reproductive issues","volume":"7","author":"Devi","year":"2009","journal-title":"Reprod Biol Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/S1043-2760(98)00027-7","article-title":"Dufau prolactin receptor gene diversity: Structure and regulation","volume":"9","author":"Hu","year":"1998","journal-title":"Trends Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1210\/endo.143.6.8949","article-title":"Complex 5' genomic structure of the human prolactin receptor: multiple alternative exons 1 and promoter utilization","volume":"143","author":"Hu","year":"2002","journal-title":"Endocrinology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M512826200","article-title":"A novel estradiol\/estrogen receptor alpha-dependent transcriptional mechanism controls expression of the human prolactin receptor","volume":"281","author":"Dong","year":"2006","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.05337-11","article-title":"Complex formation and interactions between transcription factors essential for human prolactin receptor gene transcription","volume":"31","author":"Kang","year":"2011","journal-title":"Mol Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jsbmb.2003.10.008","article-title":"Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells","volume":"88","author":"Gutzman","year":"2004","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.01.004","article-title":"Progesterone induces expression of the prolactin receptor gene through cooperative action of Sp1 and C\/EBP","volume":"335","author":"Goldhar","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.3390\/cancers13184685","article-title":"Crosstalk between PRLR and EGFR\/HER2 signaling pathways in breast cancer","volume":"13","author":"Kavarthapu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.9.4031","article-title":"A single phosphotyrosine residue of the prolactin receptor is responsible for activation of gene transcription","volume":"92","author":"Lebrun","year":"1995","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1677\/joe.0.1470011","article-title":"Cytokine receptor signalling through two novel families of transducer molecules: Janus kinases, and signal transducers and activators of transcription","volume":"147","author":"Finidori","year":"1995","journal-title":"J Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-15-5-627","article-title":"Transcriptional regulation by the helix bundle peptide hormones: Growth hormone, prolactin, and hematopoietic cytokines","volume":"15","author":"Horseman","year":"1994","journal-title":"Endocr Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81277-5","article-title":"STATs: signal transducers and activators of transcription","volume":"84","author":"Ihle","year":"1996","journal-title":"Cell"},{"key":"B49","article-title":"Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells","volume":"13","author":"Das","year":"1996","journal-title":"Oncogene"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/BF01806209","article-title":"Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells","volume":"40","author":"Das","year":"1996","journal-title":"Breast Cancer Res Treat"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/bies.950180204","article-title":"STATs and MAPKs: Obligate or opportunistic partners in signaling","volume":"18","author":"Ihle","year":"1996","journal-title":"Bioessays"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0190347","article-title":"Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells","volume":"19","author":"al-Sakkaf","year":"1997","journal-title":"J Mol Endocrinol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/me.2004-0443","article-title":"Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor","volume":"19","author":"Miller","year":"2005","journal-title":"Mol Endocrinol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210264","article-title":"Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells","volume":"26","author":"Miller","year":"2007","journal-title":"Oncogene"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/endo.138.12.5605","article-title":"Expression of prolactin and its receptor in human breast carcinoma","volume":"138","author":"Reynolds","year":"1997","journal-title":"Endocrinology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jcte.2015.05.001","article-title":"The prolactin receptor: Diverse and emerging roles in pathophysiology","volume":"2","author":"Gorvin","year":"2015","journal-title":"J Clin Transl Endocrinol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10549-010-1025-6","article-title":"Amplification of the prolactin receptor gene in mammary lobular neoplasia","volume":"128","author":"Tran-Thanh","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu150","article-title":"Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort","volume":"25","author":"Tikk","year":"2014","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.7.629","article-title":"Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women","volume":"91","author":"Hankinson","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.01.032","article-title":"Prolactin and breast cancer risk","volume":"243","author":"Tworoger","year":"2006","journal-title":"Cancer Lett"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3369","article-title":"Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women","volume":"66","author":"Tworoger","year":"2006","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.6356","article-title":"A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer","volume":"25","author":"Tworoger","year":"2007","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2559.2008.03059.x","article-title":"Prolactin receptor expression in gynaecomastia and male breast carcinoma","volume":"53","author":"Ferreira","year":"2008","journal-title":"Histopathology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-12114-7_9","article-title":"Modeling prolactin actions in breast cancer in vivo: Insights from the NRL-PRL mouse","volume":"846","author":"O\u2019Leary","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206619","article-title":"Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice","volume":"22","author":"Rose-Hellekant","year":"2003","journal-title":"Oncogene"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1494","article-title":"Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas","volume":"95","author":"Courtillot","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2372","article-title":"Gain-of-function prolactin receptor variants are not associated with breast cancer and multiple fibroadenoma risk","volume":"101","author":"Chakhtoura","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-010-0596-y","article-title":"Association of gene polymorphisms in prolactin and its receptor with breast cancer risk in Taiwanese women","volume":"38","author":"Mong","year":"2011","journal-title":"Mol Biol Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1210\/me.2002-0422","article-title":"Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase\/Erk1\/2 and phosphatidylinositol 3-kinase pathways","volume":"17","author":"Acosta","year":"2003","journal-title":"Mol Endocrinol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2376","article-title":"Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ER\u03b1 and STAT5","volume":"5","author":"Kavarthapu","year":"2014","journal-title":"Oncotarget"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2011.06.014","article-title":"Prolactin-stimulated activation of ERK1\/2 mitogen-activated protein kinases is controlled by PI3-kinase\/Rac\/PAK signaling pathway in breast cancer cells","volume":"23","author":"Aksamitiene","year":"2011","journal-title":"Cell Signal"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3249766","DOI":"10.1155\/2022\/3249766","article-title":"Matrix metalloproteinases in chemoresistance: Regulatory roles, molecular interactions, and potential inhibitors","volume":"2022","author":"Tune","year":"2022","journal-title":"J Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.447631","article-title":"Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells","volume":"288","author":"Barcus","year":"2013","journal-title":"J Biol Chem"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10137","article-title":"Prolactin signaling through focal adhesion complexes is amplified by stiff extracellular matrices in breast cancer cells","volume":"7","author":"Barcus","year":"2016","journal-title":"Oncotarget"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e0116891","DOI":"10.1371\/journal.pone.0116891","article-title":"Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells","volume":"10","author":"Barcus","year":"2015","journal-title":"PloS One"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.726190","article-title":"Identification of NEK3 kinase threonine 165 as a novel regulatory phosphorylation site that modulates focal adhesion remodeling necessary for breast cancer cell migration","volume":"291","author":"Harrington","year":"2016","journal-title":"J Biol Chem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.473","article-title":"Activation of the unliganded estrogen receptor by prolactin in breast cancer cells","volume":"28","author":"Gonz\u00e1lez","year":"2009","journal-title":"Oncogene"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1758","article-title":"Synergistic activation of ER\u03b1 by estrogen and prolactin in breast cancer cells requires tyrosyl phosphorylation of PAK1","volume":"76","author":"Oladimeji","year":"2016","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/biomedicines8090316","article-title":"Involvement of STAT5 in oncogenesis","volume":"8","author":"Halim","year":"2020","journal-title":"Biomedicines"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2013.03.010","article-title":"Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer","volume":"382","author":"Walker","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.046","article-title":"Signal transducer and activator of transcription-5 activation and breast cancer prognosis","volume":"22","author":"Nevalainen","year":"2004","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"13506","DOI":"10.1038\/s41598-021-92830-8","article-title":"Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer","volume":"11","author":"Woock","year":"2021","journal-title":"Sci Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.090399","article-title":"PTP1B suppresses prolactin activation of Stat5 in breast cancer cells","volume":"177","author":"Johnson","year":"2010","journal-title":"Am J Pathol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208203","article-title":"Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells","volume":"24","author":"Sultan","year":"2005","journal-title":"Oncogene"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16040","article-title":"Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells","volume":"8","author":"Kavarthapu","year":"2017","journal-title":"Oncotarget"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-10-0130","article-title":"Prolactin receptor-integrin cross-talk mediated by SIRP\u03b1 in breast cancer cells","volume":"8","author":"Galbaugh","year":"2010","journal-title":"Mol Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0326","article-title":"Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells","volume":"17","author":"Rasmussen","year":"2010","journal-title":"Endocrine-Related Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1210\/me.2004-0339","article-title":"Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1\/2-mediated signals to c-fos","volume":"19","author":"Gutzman","year":"2005","journal-title":"Mol Endocrinol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jsbmb.2017.04.011","article-title":"Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models","volume":"176","author":"Leehy","year":"2018","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.09.017","article-title":"Role of phosphorylation in progesterone receptor signaling and specificity","volume":"357","author":"Hagan","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-16-0121","article-title":"Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies","volume":"23","author":"Murphy","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00245","article-title":"Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy","volume":"10","author":"Rani","year":"2019","journal-title":"Front Endocrinol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11579","article-title":"Role of EGF\/ERBB1 in the transcriptional regulation of the prolactin receptor independent of estrogen and prolactin in breast cancer cells","volume":"7","author":"Kavarthapu","year":"2016","journal-title":"Oncotarget"},{"key":"B97","doi-asserted-by":"publisher","first-page":"428062","DOI":"10.5402\/2012\/428062","article-title":"Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer","volume":"2012","author":"Nahta","year":"2012","journal-title":"ISRN Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.5144\/1658-3876.2012.127","article-title":"Targeting the HER2 receptor in metastatic breast cancer","volume":"5","author":"Orphanos","year":"2012","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41523-021-00265-1","article-title":"HER2-positive breast cancer and tyrosine kinase inhibitors: The time is now","volume":"7","author":"Schlam","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.09.029","article-title":"Better together: Targeted combination therapies in breast cancer","volume":"42","author":"Zanardi","year":"2015","journal-title":"Semin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14526","article-title":"Phase I study of LFA102 in patients with advanced breast cancer or castration-resistant prostate cancer","volume":"40","author":"Minami","year":"2020","journal-title":"Anticancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9789-z","article-title":"Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells","volume":"111","author":"Scotti","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: Targets, trials and biomarkers","volume":"6","author":"Paplomata","year":"2014","journal-title":"Ther Adv Med Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.949396\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T07:13:09Z","timestamp":1663225989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.949396\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":103,"alternative-id":["10.3389\/fendo.2022.949396"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.949396","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"949396"}}